Buy CJC 1295 & Ipamorelin Blend (10mg) (No DAC)

CJC-1295 & Ipamorelin Blend Product Description

CJC-1295 is a long-acting GHRH analog that binds to endogenous albumin, significantly prolonging half-life. CJC-1295 without DAC (often called Modified GRF 1-29 or CJC-1295 no DAC) retains 29 amino acids from natural GHRH but includes four substitutions to enhance stability and receptor binding. This potentially mimics a more natural pulsatile GH release pattern.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective growth hormone secretagogue (GHS) that mimics ghrelin, a hormone that stimulates the release of growth hormone from the pituitary gland. It is known for its high potency and efficacy in releasing GH without significantly affecting other hormones like ACTH or cortisol, making it a unique candidate among growth hormone secretagogues.

The peptide blend may amplify GH release by targeting both GHRH and ghrelin receptors.

This is a (10mg) blend each of CJC-1295 (No DAC) (5mg) and Ipamorelin (5mg).

CJC 1295 Ipamorelin Research

CJC-1295 and ipamorelin have both been researched for their potential to stimulate growth hormone production.

Growth Hormone Release

In GHRH knockout mice, CJC-1295 administration normalized body weight and length, demonstrating its potential in treating growth deficiencies. Daily administration was more effective than less frequent dosing.¹

In healthy subjects, CJC-1295 led to dose-dependent increases in GH and IGF-I levels, with effects lasting up to 28 days. In the study, CJC-1295 was well-tolerated with no serious adverse reactions reported, suggesting its potential utility as a therapeutic agent.²

Ipamorelin mimics the action of ghrelin by binding to the ghrelin receptor (GHSR) in the brain, which leads to the selective stimulation of GH release from the pituitary gland. This mechanism is similar to that of GHRH, but ipamorelin does not significantly affect the release of other hormones such as ACTH or cortisol.³

In animal studies, ipamorelin has been shown to increase longitudinal bone growth and body weight gain in a dose-dependent manner. It enhances GH release without affecting other growth factors like IGF-I, suggesting a direct effect on growth processes.⁴

In vivo, ipamorelin shows dose-proportional pharmacokinetics with a short half-life and effectively stimulated GH release across various doses.⁵

References

1. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J., Frohman, L., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American journal of physiology. Endocrinology and metabolism, 291 6, E1290-4 . https://doi.org/10.1152/AJPENDO.00201.2006.
2. Teichman, S., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J., & Frohman, L. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 91 3, 799-805 . https://doi.org/10.1210/JC.2005-1536.
3. Raun, K., Hansen, B., Johansen, N., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology, 139 5, 552-61 . https://doi.org/10.1530/EJE.0.1390552.
4. Johansen, P., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 9 2, 106-13 . https://doi.org/10.1054/GHIR.1999.9998.
5. Gobburu, J., Agersø, H., Jusko, W., & Ynddal, L. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research, 16, 1412-1416. https://doi.org/10.1023/A:1018955126402.

CJC-1295 No DAC Ipamorelin (260403)

CJC-1295 No DAC / Ipamorelin (260257)

Endotoxin Ipamorelin

CJC-1295 Ipamorelin (11383)

CJC-1295 Ipamorelin (11383)

CJC-1295 no DAC / Ipamorelin

CJC-1295 no DAC / Ipamorelin

CJC-1295 no DAC & Ipamorelin (251527)

CJC-1295 no DAC & Ipamorelin (251527E)

CJC-1295/IPAMORELIN(251432)

CJC-1295/Ipamorelin (250971)

CJC-1295 no DAC/Ipamorelin Blend BL-ENDO-250409-001

Ipamorelin(10181)

CJC1295(10181)

×

Disclaimer: For Research Purposes Only

This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides. . .